Wedbush Reaffirms Their Buy Rating on Allena Pharmaceuticals Inc


In a report released yesterday, Liana Moussatos from Wedbush reiterated a Buy rating on Allena Pharmaceuticals Inc (NASDAQ: ALNA), with a price target of $38. The company’s shares closed yesterday at $14.76.

According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 10.1% and a 44.3% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Catabasis Pharmaceuticals, and Miragen Therapeutics Inc.

Currently, the analyst consensus on Allena Pharmaceuticals Inc is Strong Buy and the average price target is $40.83, representing a 176.6% upside.

In a report issued on May 9, Cowen & Co. also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

The company has a one-year high of $17.56 and a one-year low of $6.13. Currently, Allena Pharmaceuticals Inc has an average volume of 109.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company, which engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts